Sigma-Tau Pharmaceuticals, Inc.

Pharmaceutical manufacturer and distributor developing or acquiring and making available products based on naturally-occurring substances that enhance the body's natural ability to maintain its health state. Sigma-Tau is the worldwide leader in carnitine and metabolic research. Established in 1980, Sigma-Tau Pharmaceuticals, Inc. began commercial operations in the United States in 1989. Sigma-Tau Pharmaceuticals, Inc. is the U.S. subsidiary of Sigma-Tau S.p.A., the leading research-based Italian pharmaceutical company, with subsidiaries worldwide. Sigma-Tau is committed to developing and ensuring the availability of specialized products for unmet medical needs such as those that commonly receive a misdiagnosis (an incorrect diagnosis) or a missed diagnosis (no diagnosis). Among the products that Sigma-Tau develops and produces are orphan drugs-drugs with a treatment population of fewer than 200,000 patients. For example, Sigma-Tau offers Carnitor®(levocarnitine), the only prescription form of levocarnitine available for the treatment of carnitine deficiency.

Activity:

- Manufacturing
- Sales & Distribution

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: